1-3 of 3
John Chadwick
Close
Sort by
Journal Articles

Therapeutic Targeting of EP300/CBP By Bromodomain Inhibition in Acute Myeloid Leukemia

Luciano Nicosia, Gary J Spencer, Nigel Brooks, Fabio Amaral, Naseer Basma, John Chadwick, Bradley Revell, Bettina Wingelhofer, Alba Maiques-Diaz, Filippo Ciceri, Daniel H Wiseman, Neil A Pegg, William West, Tomasz Knurowski, Kris Frese, Karen Clegg, Victoria Louise Campbell, Mhairi Copland, Emma Searle, Tim C.P Somervaille
Journal: Blood
Blood (2022) 140 (Supplement 1): 8774–8775.
https://doi.org/10.1182/blood-2022-166260
Published: 2022
Journal Articles

CCS1477, a Novel p300/CBP Bromodomain Inhibitor, Enhances Efficacy of Azacitidine and Venetoclax in Pre-Clinical Models of Acute Myeloid Leukaemia and Lymphoma

Nigel Brooks, Tomasz Knurowski, Andrew Hughes, Karen Clegg, William West, Neil A Pegg, Gary J Spencer, John Chadwick, Tim C.P Somervaille
Journal: Blood
Blood (2021) 138 (Supplement 1): 3291.
https://doi.org/10.1182/blood-2021-148295
Published: 2021
Journal Articles

Advanced Age at Transplant Increases the Risk of Second Solid Malignancy (SSM) after Haematopoetic Stem Cell Transplantation (HSCT)

John Murray, RGN, MSc, John Chadwick, MRCP, Adrian Bloor, PhD FRCPath, Jim Cavet, FRCPath, Mike Dennis, FRCPath, Tim Somervaille, FRCPath, Sven Armin Sommerfeld, MRCP, John Eliott, MRCP, Siobhan Muthia, MRCP, Angie Leather, RGN BSc, Rita Angelica, RGN BSc, Rachel Brown, MRCP, Jo Tomlins, MSc, Samar Kulkarni, FRCPath
Journal: Blood
Blood (2014) 124 (21): 3952.
https://doi.org/10.1182/blood.V124.21.3952.3952
Published: 2014